ZBH · 8-K · 20260805PR333761
Guidance / Outlook
ZIMMER BIOMET HOLDINGS, INC. · 2026-08-05 · Importance 78 · Surprise 84 · No source text
Zimmer Biomet raised its full-year 2026 reported revenue growth guidance to 3.9%–4.9% from 2.5%–4.5%. Constant-currency revenue growth guidance increased to 3.4%–4.4%, while organic constant-currency growth guidance increased to 2.25%–3.25%, excluding approximately 110 basis points from the Paragon 28 acquisition through its one-year anniversary. Adjusted diluted EPS guidance was increased to $8.47–$8.59 from $8.40–$8.55 for the year ending December 31, 2026.
Key facts
- Company updated full-year 2026 reported revenue change guidance from 2.5% - 4.5% to 3.9% - 4.9% source
- Company updated full-year 2026 constant currency revenue change guidance from 2.0% - 4.0% to 3.4% - 4.4% source
- Company updated full-year 2026 adjusted diluted EPS guidance from $8.40 - $8.55 to $8.47 - $8.59 source
- Company updated full-year 2026 organic constant currency revenue change guidance from 1.0% - 3.0% to 2.25% - 3.25% source
- Foreign currency exchange impact for 2026 guidance presented as +0.5% (unchanged) source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | committed | +0.8% | Company updated full-year 2026 reported revenue change guidance from 2.5% - 4.5% to 3.9% - 4.9% |
| revenue | positive | committed | +0.6% | Company updated full-year 2026 organic constant currency revenue change guidance from 1.0% - 3.0% to 2.25% - 3.25% |
| net_income | positive | committed | — | Company updated full-year 2026 adjusted diluted EPS guidance from $8.40 - $8.55 to $8.47 - $8.59 |